Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew D Hellmann; Naiyer A Rizvi; Jonathan W Goldman; Scott N Gettinger; Hossein Borghaei; Julie R Brahmer; Neal E Ready; David E Gerber; Laura Q Chow; Rosalyn A Juergens; Frances A Shepherd; Scott A Laurie; William J Geese; Shruti Agrawal; Tina C Young; Xuemei Li; Scott J Antonia

doi:10.1016/s1470-2045(16)30624-6

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

The Lancet Oncology ◽

10.1016/s1470-2045(16)30624-6 ◽

2017 ◽

Vol 18 (1) ◽

pp. 31-41 ◽

Cited By ~ 430

Author(s):

Matthew D Hellmann ◽

Naiyer A Rizvi ◽

Jonathan W Goldman ◽

Scott N Gettinger ◽

Hossein Borghaei ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase 1 ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727089161.793539631 ◽

2017 ◽

Author(s):

Patrick Nana-Sinkam

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase 1 ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

Lung Cancer ◽

10.1016/s0169-5002(16)30086-1 ◽

2016 ◽

Vol 91 ◽

pp. S25

Author(s):

K.J. O'Byrne ◽

K. Park ◽

E. Tan ◽

L. Zhang ◽

V. Hirsh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)

Annals of Oncology ◽

10.1093/annonc/mdv586.02 ◽

2015 ◽

Vol 26 ◽

pp. ix161 ◽

Cited By ~ 10

Author(s):

K. Park ◽

E.-H. Tan ◽

L. Zhang ◽

V. Hirsh ◽

K. O'Byrne ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7583 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7583-7583

Author(s):

L. Faoro ◽

J. D. Hainsworth ◽

D. A. Karlin ◽

J. E. Huang ◽

L. Fang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3181f94ad4 ◽

2011 ◽

Vol 6 (1) ◽

pp. 109-114 ◽

Cited By ~ 41

Author(s):

John D. Hainsworth ◽

Liang Fang ◽

Jane E. Huang ◽

David Karlin ◽

Kenneth Russell ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30167-6 ◽

2019 ◽

Vol 20 (7) ◽

pp. 924-937 ◽

Cited By ~ 202

Author(s):

Howard West ◽

Michael McCleod ◽

Maen Hussein ◽

Alessandro Morabito ◽

Achim Rittmeyer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

P-550 Phase 1–2 dose-ranging trial of TLK286 (TELCYTA) and Cisplatin (C) as first-line treatment in advanced non-small cell lung cancer (NSCLC)

Lung Cancer ◽

10.1016/s0169-5002(05)81043-8 ◽

2005 ◽

Vol 49 ◽

pp. S262 ◽

Cited By ~ 1

Author(s):

V. Papadimitrakopoulou ◽

M. Edelman ◽

R. Zinner ◽

G. Blumenschein ◽

S. Jones ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 1 ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Dose Ranging ◽

First Line Treatment

Download Full-text

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-014-2478-9 ◽

2014 ◽

Vol 74 (1) ◽

pp. 37-43 ◽

Cited By ~ 7

Author(s):

Hidehito Horinouchi ◽

Noboru Yamamoto ◽

Hiroshi Nokihara ◽

Takeshi Horai ◽

Makoto Nishio ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase 1 ◽

Japanese Patients ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase 1 Study ◽

First Line Treatment

Download Full-text

Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8005 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8005-8005 ◽

Cited By ~ 10

Author(s):

Terufumi Kato ◽

Takashi Seto ◽

Makoto Nishio ◽

Koichi Goto ◽

Shinji Atagi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Trial ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Treatment

Download Full-text

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70184-x ◽

2011 ◽

Vol 12 (8) ◽

pp. 735-742 ◽

Cited By ~ 2256

Author(s):

Caicun Zhou ◽

Yi-Long Wu ◽

Gongyan Chen ◽

Jifeng Feng ◽

Xiao-Qing Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text